Abstract
Introduction: Convalescent plasma transfusion (CPT), a potential therapy for coronavirus disease 2019 (COVID-19), requires strict quality control of the donor blood. Whether to confirm the disappearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA (RNAemia) in convalescent donor blood or not is unclear. Reports recommending the proof of viral disappearance from the blood are controversial. Foreseeing CPT in treating COVID-19 patients in Japan, we investigated RNAemia in 100 convalescent donors with mild, moderate, and severe COVID-19.
Methods: Between April 30 and July 30, 2020, we measured RNAemia in the plasma samples of donors with resolved COVID-19. Data on patients’ demographics, comorbidities, pneumonia, treatment, and real-time polymerase chain reaction results for SARS-CoV-2 were collected. Date of onset of initial symptoms or date of positive testing (for asymptomatic patients) were self-reported by the patients. Disease severity was defined as: no, mild, moderate oxygen demand, or severe (requiring mechanical ventilation).
Results: Of 100 donors (58 males [58.0%]; median age, 47 [range 22-69] years) screened as of July 30, 2020, 77 (77.0%); 19 (19.0%); and 4 (4.0%) had mild, moderate, and severe disease, respectively. Median time between onset and testing was 68.5 (range, 21-167) days. SARS-CoV-2 RNA was not detected in any of the plasma samples.
Conclusion: RNAemia was not found in recovered COVID-19 patients at least 21, 27, and 57 days after the onset of mild, moderate, and severe symptoms. Our study may contribute to determining a suitable time for collecting convalescent plasma from COVID-19 patients and to future CPT use.
Keywords: Convalescent plasma; Coronavirus 2019; Passive immunization; RNA; Severe acute respiratory syndrome coronavirus 2.
【저자키워드】 severe acute respiratory syndrome coronavirus 2, convalescent plasma, passive immunization, RNA, Coronavirus 2019, 【초록키워드】 COVID-19, Treatment, coronavirus disease, severe acute respiratory syndrome coronavirus 2, convalescent plasma, passive immunization, SARS-CoV-2, Coronavirus disease 2019, coronavirus, severe COVID-19, mechanical ventilation, Pneumonia, severity, disease severity, Comorbidities, oxygen, severe acute respiratory syndrome Coronavirus, polymerase chain reaction, real-time polymerase chain reaction, male, Patient, Japan, Mild, SARS-CoV-2 RNA, donors, Quality control, convalescent, moderate, asymptomatic patients, patients, COVID-19 patients, Blood, Donor, Recovered COVID-19 patients, severe disease, COVID-19 patient, Plasma transfusion, demographics, Chain Reaction, initial symptoms, date of onset, oxygen demand, initial symptom, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, median time, median age, plasma samples, severe symptoms, proof, disappearance, report, positive, potential therapy, recovered COVID-19 patient, plasma sample, polymerase chain, donor blood, defined, collected, investigated, screened, contribute, resolved, Passive, treating COVID-19 patient, 【제목키워드】 COVID-19 patient,